Novartis MS drug remibrutinib seen advantaged on liver safety
Citi analysts said Novartis’s late-stage multiple sclerosis studies for remibrutinib reported no liver-safety signals, potentially differentiating it from a Roche rival drug based on safety profile.
Citi analysts said Novartis’s new multiple sclerosis drug may stand apart from a rival product Roche Holding is developing because of its safety profile. Novartis said it saw no liver-safety signals in late-stage studies of remibrutinib in multiple sclerosis, while Roche…